Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase 1 trial resultsKelly C. Goldsmith, Yaël P. Mossé, Yueh‐Yun Chi et al.|Nature Medicine|2023Cited by 125
Novel Statistical Analyses to Assess Hearing Outcomes After ABI Implantation in NF2 Patients: Systematic Review and Individualized Patient Data AnalysisShervin Taslimi, Farhad Pirouzmand, Jeffrey Zuccato et al.|World Neurosurgery|2019Cited by 6